| [1] |
MENG Fanzheng, ZHANG Feng, ZHENG Guohao, LIU Lianxin.
The role and status of different conversion therapies in the treatment of primary liver cancer
[J]. JOURNAL OF CLINICAL SURGERY, 2026, 34(1): 6-10.
|
| [2] |
XU Ziling, JIA Weidong.
Interpretation of international guidelines for selective internal radiation therapy with Yttrium-90 microspheres in hepatocellular carcinoma
[J]. JOURNAL OF CLINICAL SURGERY, 2026, 34(1): 11-15.
|
| [3] |
.
Relationship of the Cyclin B2 and Cyclin E1 expression with clinicopathological characteristics and 5-year survival rate of patients with hepatocellular carcinoma
[J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(9): 981-984.
|
| [4] |
PAN Junhao, WANG Chunhui.
Constructing a prognostic prediction model for distant metastatic hepatocellular carcinoma based upon SEER data
[J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(4): 410-415.
|
| [5] |
Chinese Chapter of the International Hepato-Pancreato-Biliary Association, Hepatic Surgery Group of Surgical Branch of Chinese Medical Association.
Expert consensus on safety assessment of hepatectomy for hepatocellular carcinoma with HBV-related liver cirrhosis
[J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(3): 225-236.
|
| [6] |
WANG Hao,Liang Binyong,MEI Bin.
Progress in neoadjuvant therapy for hepatocellular carcinoma based on immune checkpoint inhibitors
[J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(3): 332-335.
|
| [7] |
YANG Xin, XU Da, QIN Lunxiu.
The current situation and challenges of liver resection for hepatocellular cancinoma
[J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(10): 1048-1052.
|
| [8] |
TANG Haowen, CAO Yinbiao, LU Shichun.
Novel strategies for the management of hepatocellular carcinoma with portal vein tumor thrombus
[J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(10): 1053-1057.
|
| [9] |
ZHAN Xuezhi, YU Jin, ZHU Yuan, LIAO Xiaofeng, LI Xiaogang.
The influence of preoperative transarterial chemoembolizationon the early recurrence of stage Ⅰb-Ⅱa diagnosed liver cancer
[J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(10): 1073-1076.
|
| [10] |
HUANG Hongwei,CHEN Qi,LIAO Wei,ZHANG Kaiyue,WANG Hao,MEI Bin.
Postoperative adjuvant immunotherapy for huge hepatocellular carcinoma in China liver cancer staging Ⅲa
[J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(4): 386-390.
|
| [11] |
ZHOU Yi,LIANG Binyong,XIAO Zhenyu.
Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
[J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(3): 328-331.
|
| [12] |
XIONG Jianwei, LI Qiang, TANG Tao, ZHANG Lixin, YING Bao, ZHAO Kaifeng, XIONG Yongfu, LI Jingdong, WU Guo.
Efficacy and safety of transhepatic arterial chemoembolization combined with tyrosine kinase inhibitor and programmed death receptor-1 inhibitors in the treatment of intermediate and a-dvanced unresectable hepatocellular carcinoma
[J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(2): 176-181.
|
| [13] |
XIE Zhenhui,HUANG Zhiyong.
Effect of Pringle maneuver on prognosis of patients with hepatocellular carcinoma during hepatectomy
[J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(12): 1340-1342.
|
| [14] |
MU Xixi, LI Jing, ZHANG Xuan, et al.
Expression levels and clinical diagnostic value of miR-3619-5p and LINC00857 in serum of hepatocellular carcinoma
[J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(6): 572-575.
|
| [15] |
LIU Jinwei, BA Linchao, ZHANG Jingfu, et al.
Expression of hypoxia-induced lipid droplet-associated protein in hepatocellular carcinoma and clinical significance
[J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(5): 447-452.
|